{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:36:23Z","timestamp":1792499783264,"version":"4.5.0"},"reference-count":228,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24 AI183182"],"award-info":[{"award-number":["K24 AI183182"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI183668"],"award-info":[{"award-number":["1R01AI183668"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54 DK104309"],"award-info":[{"award-number":["U54 DK104309"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,8,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Antimicrobial resistance poses a major challenge in the treatment of\n                      <jats:italic toggle=\"yes\">Acinetobacter baumannii. Acinetobacter<\/jats:italic>\n                      spp. are intrinsically resistant to a number of commonly used antibiotics. Over the past 3 years, the European and American Professional Societies have provided important guidelines on the treatment options for carbapenem-resistant\n                      <jats:italic toggle=\"yes\">A. baumannii<\/jats:italic>\n                      (CRAB). Here, we review the recent literature on combination regimens for CRAB as well as carbapenem-susceptible\n                      <jats:italic toggle=\"yes\">A. baumannii<\/jats:italic>\n                      infections. We discuss the strengths and weaknesses of various agents used in combination, depending on the site of infection and their pharmacokinetic properties. Consistent with the 2024 Infectious Diseases of America (IDSA) update, sulbactam-durlobactam, in combination with background carbapenem therapy, remains the combination with the greatest reduction in mortality for pulmonary infections and has promising outcomes in bloodstream infections with CRAB. Sulbactam-based combination therapy remains an ideal part of targeted strategies and has been shown to be associated with reduced mortality. Certain agents have been highlighted in the literature for suboptimal outcomes, primarily pulmonary infections treated with cefiderocol, tigecycline, and eravacycline. Studies including non-pulmonary infections, specifically bacteremia and central nervous system (CNS) infections, are overall limited to case series and subgroup analyses. Important areas for further research include breakpoint evaluations for eravacycline and minocycline as well as subclinical resistance in cefiderocol.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01063-24","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T13:47:31Z","timestamp":1752068851000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":56,"title":["<i>Acinetobacter baumannii<\/i>\n                    treatment strategies: a review of therapeutic challenges and considerations"],"prefix":"10.1128","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-440X","authenticated-orcid":true,"given":"Christine J.","family":"Kubin","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0530xmm89","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons","place":["New York, USA"]},{"id":[{"id":"https:\/\/ror.org\/01j17xg39","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy, NewYork-Presbyterian Hospital","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2728-3373","authenticated-orcid":true,"given":"Christopher","family":"Garzia","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01j17xg39","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy, NewYork-Presbyterian Hospital","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9798-4768","authenticated-orcid":true,"given":"Anne-Catrin","family":"Uhlemann","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0530xmm89","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/15.4.748"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1099\/ijs.0.000043"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1099\/ijsem.0.001318"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02992-14"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"e_1_3_1_7_2","volume-title":"WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance","author":"WHO","year":"2024","unstructured":"WHO. 2024. WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. World Health Organization, Geneva."},{"key":"e_1_3_1_8_2","volume-title":"Antibiotic resistance threats in the United States","author":"CDC","year":"2019","unstructured":"CDC. 2019. Antibiotic resistance threats in the United States. US Department of Health and Human Services, Atlanta, GA."},{"key":"e_1_3_1_9_2","volume-title":"Tygacil [package insert]","author":"CDC","year":"2010","unstructured":"CDC. 2010. Tygacil [package insert]. Wyeth Pharmaceuticals Inc, Philadelphia, PA."},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/500202"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2006.11.010"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/529198"},{"key":"e_1_3_1_13_2","unstructured":"CDC. 2021. HAI pathogens and antimicrobial resistance report 2018-2021 on US Department of Health and Human Services. https:\/\/www.cdc.gov\/nhsn\/datastat\/ar-pathogens.html."},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02562-17"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-014-0572-6"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.16902"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad100"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12363"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-07024-4"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01975-21"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1754"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad094"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.11.025"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07436-w"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.4.750"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.1.138"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41426-018-0038-9"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2022.08.002"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2024.04.184"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00781-22"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02534-19"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/504477"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00036-08"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2023.11908"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-52-12-1125"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.10.2265"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.9.3978-3984.2004"},{"key":"e_1_3_1_38_2","first-page":"425","article-title":"Study on the molecular epidemiology of SHV type beta-lactamase-encoding genes of multiple-drug-resistant Acinetobacter baumannii","volume":"25","author":"Huang Z","year":"2004","unstructured":"Huang Z, Mao P, Chen Y, Wu L, Wu J. 2004. Study on the molecular epidemiology of SHV type beta-lactamase-encoding genes of multiple-drug-resistant Acinetobacter baumannii. Zhonghua Liu Xing Bing Xue Za Zhi 25:425\u2013427.","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom10050720"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad109"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02759-21"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01512-08"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161213804070285"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky359"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02260-23"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1086\/375821"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/38.2.245"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2019.190103"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0599-2020"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00514-21"},{"key":"e_1_3_1_51_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12030516"},{"key":"e_1_3_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30796-9"},{"key":"e_1_3_1_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad428"},{"key":"e_1_3_1_54_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403"},{"key":"e_1_3_1_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04808-14"},{"key":"e_1_3_1_56_2","volume-title":"CLSI supplement M100","author":"CLSI","year":"2024","unstructured":"CLSI. 2024. Performance standards for antimicrobial susceptibility testing. In CLSI supplement M100, 34th ed. Clinical and Laboratory Standards Institute, USA.","edition":"34"},{"key":"e_1_3_1_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.02.012"},{"key":"e_1_3_1_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae218"},{"key":"e_1_3_1_59_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.833189"},{"key":"e_1_3_1_60_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijccm.IJCCM_302_17"},{"key":"e_1_3_1_61_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540600951184"},{"key":"e_1_3_1_62_2","doi-asserted-by":"publisher","DOI":"10.4266\/kjccm.2015.00703"},{"key":"e_1_3_1_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.08.021"},{"key":"e_1_3_1_64_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1916-6"},{"key":"e_1_3_1_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.01.016"},{"key":"e_1_3_1_66_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S225518"},{"key":"e_1_3_1_67_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn165"},{"key":"e_1_3_1_68_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh125"},{"key":"e_1_3_1_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.01.020"},{"key":"e_1_3_1_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106930"},{"key":"e_1_3_1_71_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00345-17"},{"key":"e_1_3_1_72_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1083464"},{"key":"e_1_3_1_73_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-020-00715-2"},{"key":"e_1_3_1_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.10.033"},{"key":"e_1_3_1_75_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04987-14"},{"key":"e_1_3_1_76_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-019-0502-x"},{"key":"e_1_3_1_77_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01235-y"},{"key":"e_1_3_1_78_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1141490"},{"key":"e_1_3_1_79_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01099-06"},{"key":"e_1_3_1_80_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01981-23"},{"key":"e_1_3_1_81_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01154-19"},{"key":"e_1_3_1_82_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0636-6"},{"key":"e_1_3_1_83_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01809-20"},{"key":"e_1_3_1_84_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms7060159"},{"key":"e_1_3_1_85_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-017-0153-2"},{"key":"e_1_3_1_86_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu593"},{"key":"e_1_3_1_87_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01680-20"},{"key":"e_1_3_1_88_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad020"},{"key":"e_1_3_1_89_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0545-8"},{"key":"e_1_3_1_90_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04809-14"},{"key":"e_1_3_1_91_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00436-16"},{"key":"e_1_3_1_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.06.022"},{"key":"e_1_3_1_93_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae220"},{"key":"e_1_3_1_94_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00479-22"},{"key":"e_1_3_1_95_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2908"},{"key":"e_1_3_1_96_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221085551"},{"key":"e_1_3_1_97_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1029"},{"key":"e_1_3_1_98_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.4237"},{"key":"e_1_3_1_99_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm201467r"},{"key":"e_1_3_1_100_2","doi-asserted-by":"publisher","DOI":"10.4103\/0975-7406.142949"},{"key":"e_1_3_1_101_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz827"},{"key":"e_1_3_1_102_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01990-21"},{"key":"e_1_3_1_103_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaa060"},{"key":"e_1_3_1_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107167"},{"key":"e_1_3_1_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107047"},{"key":"e_1_3_1_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.01.012"},{"key":"e_1_3_1_107_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-09899-5"},{"key":"e_1_3_1_108_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S475462"},{"key":"e_1_3_1_109_2","doi-asserted-by":"crossref","unstructured":"Clancy N. 2024. Real-world effectiveness and safety of cefiderocol in the treatment of patients with serious Gram-negative bacterial infections: results of the PROVE chart review study. Poster presented at IDWeek 2024","DOI":"10.1093\/ofid\/ofae631.1645"},{"key":"e_1_3_1_110_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae146"},{"key":"e_1_3_1_111_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02371-23"},{"key":"e_1_3_1_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00194-8"},{"key":"e_1_3_1_113_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01221-20"},{"key":"e_1_3_1_114_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00234-23"},{"key":"e_1_3_1_115_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac647"},{"key":"e_1_3_1_116_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad078"},{"key":"e_1_3_1_117_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac098"},{"key":"e_1_3_1_118_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad046"},{"key":"e_1_3_1_119_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02425-14"},{"key":"e_1_3_1_120_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr299"},{"key":"e_1_3_1_121_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.000132"},{"key":"e_1_3_1_122_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr135"},{"key":"e_1_3_1_123_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03928.x"},{"key":"e_1_3_1_124_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.infpip.2021.100113"},{"key":"e_1_3_1_125_2","doi-asserted-by":"publisher","DOI":"10.1017\/ash.2021.155"},{"key":"e_1_3_1_126_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-023-00607-w"},{"key":"e_1_3_1_127_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00877-21"},{"key":"e_1_3_1_128_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2802"},{"key":"e_1_3_1_129_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2017.104"},{"key":"e_1_3_1_130_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00159-19"},{"key":"e_1_3_1_131_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01576-17"},{"key":"e_1_3_1_132_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00184-6"},{"key":"e_1_3_1_133_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2004.00987.x"},{"key":"e_1_3_1_134_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg097"},{"key":"e_1_3_1_135_2","volume-title":"Sulbactam-durlobactam (SUL-DUR) in vitro dose response studies with and without imipenem or meropenem carbapenemase-producing Acinetobacter baumannii utilizing the hollow-fiber infection model, abstr ECCMID, Lisbon, Portugal","author":"Miller A","year":"2022","unstructured":"Miller A, Tommasi R. 2022. Sulbactam-durlobactam (SUL-DUR) in vitro dose response studies with and without imipenem or meropenem carbapenemase-producing Acinetobacter baumannii utilizing the hollow-fiber infection model, abstr ECCMID, Lisbon, Portugal"},{"key":"e_1_3_1_136_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac092"},{"key":"e_1_3_1_137_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00312-23"},{"key":"e_1_3_1_138_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.1761"},{"key":"e_1_3_1_139_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae210"},{"key":"e_1_3_1_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2024.116344"},{"key":"e_1_3_1_141_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00924-21"},{"key":"e_1_3_1_142_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae140"},{"key":"e_1_3_1_143_2","doi-asserted-by":"publisher","DOI":"10.1086\/653120"},{"key":"e_1_3_1_144_2","volume-title":"Polymyxin breakpoints for Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp","author":"CLSI","year":"2020","unstructured":"CLSI. 2020. Polymyxin breakpoints for Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp. 2nd ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"2"},{"key":"e_1_3_1_145_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.11.029"},{"key":"e_1_3_1_146_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30099-9"},{"key":"e_1_3_1_147_2","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2200131"},{"key":"e_1_3_1_148_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit253"},{"key":"e_1_3_1_149_2","doi-asserted-by":"publisher","DOI":"10.1017\/S095026881200194X"},{"key":"e_1_3_1_150_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.11.016"},{"key":"e_1_3_1_151_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03510-14"},{"key":"e_1_3_1_152_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0463"},{"key":"e_1_3_1_153_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2023.2184346"},{"key":"e_1_3_1_154_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00494-15"},{"key":"e_1_3_1_155_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13030261"},{"key":"e_1_3_1_156_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00284-09"},{"key":"e_1_3_1_157_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10050528"},{"key":"e_1_3_1_158_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm305"},{"key":"e_1_3_1_159_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.2.142.34114"},{"key":"e_1_3_1_160_2","doi-asserted-by":"publisher","DOI":"10.1086\/340055"},{"key":"e_1_3_1_161_2","doi-asserted-by":"publisher","DOI":"10.1086\/374847"},{"key":"e_1_3_1_162_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00541-4"},{"key":"e_1_3_1_163_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02392-19"},{"key":"e_1_3_1_164_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.5.1586-1592.2004"},{"key":"e_1_3_1_165_2","doi-asserted-by":"publisher","DOI":"10.1086\/432623"},{"key":"e_1_3_1_166_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30731-3"},{"key":"e_1_3_1_167_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/8.supplement_5.s609"},{"key":"e_1_3_1_168_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.6.958"},{"key":"e_1_3_1_169_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.5.932"},{"key":"e_1_3_1_170_2","doi-asserted-by":"publisher","DOI":"10.1080\/02688697.2017.1319907"},{"key":"e_1_3_1_171_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(02)00276-5"},{"key":"e_1_3_1_172_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2013.837957"},{"key":"e_1_3_1_173_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S377772"},{"key":"e_1_3_1_174_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S354460"},{"key":"e_1_3_1_175_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2024.063"},{"key":"e_1_3_1_176_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.05.012"},{"key":"e_1_3_1_177_2","unstructured":"FDA. 2010. FDA drug safety communication: increased risk of death with tygacil (Tigecycline) compared to other antibiotics used to treat similar infections. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-increased-risk-death-tygacil-tigecycline-compared-other-antibiotics"},{"key":"e_1_3_1_178_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki477"},{"key":"e_1_3_1_179_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00497-10"},{"key":"e_1_3_1_180_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.11.011"},{"key":"e_1_3_1_181_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198815060-00001"},{"key":"e_1_3_1_182_2","doi-asserted-by":"publisher","DOI":"10.1159\/000048494"},{"key":"e_1_3_1_183_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02371-16"},{"key":"e_1_3_1_184_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1381123"},{"key":"e_1_3_1_185_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac391"},{"key":"e_1_3_1_186_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac248"},{"key":"e_1_3_1_187_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz123"},{"key":"e_1_3_1_188_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.4632"},{"key":"e_1_3_1_189_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac484"},{"key":"e_1_3_1_190_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00485-24"},{"key":"e_1_3_1_191_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00275-18"},{"key":"e_1_3_1_192_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02036-13"},{"key":"e_1_3_1_193_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.1760"},{"key":"e_1_3_1_194_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41429-019-0188-6"},{"key":"e_1_3_1_195_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.23.5.692"},{"key":"e_1_3_1_196_2","volume-title":"Xacduro [package insert]","author":"Anonymous","year":"2023","unstructured":"Anonymous. 2023. Xacduro [package insert]. La Jolla Pharmaceutical Company, Waltham, MA."},{"key":"e_1_3_1_197_2","volume-title":"Fetroja [package insert]","author":"Anonymous","year":"2024","unstructured":"Anonymous. 2024. Fetroja [package insert]. Shionogi & Co., Ltd. , Osaka, Japan."},{"key":"e_1_3_1_198_2","first-page":"63","article-title":"The glycylcyclines: a comparative review with the tetracyclines","volume":"64","author":"Zhanel GG","year":"2004","unstructured":"Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, Gin A, Karlowsky JA, Hoban DJ. 2004. The glycylcyclines: a comparative review with the tetracyclines. Drugs (Abingdon Engl) 64:63\u201388.","journal-title":"Drugs (Abingdon Engl)"},{"key":"e_1_3_1_199_2","volume-title":"Eravacycline [package insert]","author":"Anonymous","year":"2018","unstructured":"Anonymous. 2018. Eravacycline [package insert]. Watertown, MA."},{"key":"e_1_3_1_200_2","doi-asserted-by":"publisher","DOI":"10.21037\/tau-20-959"},{"key":"e_1_3_1_201_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl224"},{"key":"e_1_3_1_202_2","unstructured":"Anonymous. 2018. Tetraphase announces top-line results from IGNITE3 phase 3 clinical trial of eravacycline in complicated urinary tract infections (CUTI) on Tetraphase Pharmaceuticals Inc. Available from: https:\/\/ir.tphase.com\/news-releases\/news-release-details\/tetraphase-announces-top-line-results-ignite3-phase-3-clinical"},{"key":"e_1_3_1_203_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2209"},{"key":"e_1_3_1_204_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit334"},{"key":"e_1_3_1_205_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.220-229.2005"},{"key":"e_1_3_1_206_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl403"},{"key":"e_1_3_1_207_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00931-17"},{"key":"e_1_3_1_208_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2012.732705"},{"key":"e_1_3_1_209_2","volume-title":"Minocin [package insert]","author":"Anonymous","year":"2010","unstructured":"Anonymous. 2010. Minocin [package insert]. Triax Pharmaceuticals, LLC, Cincinnati, OH."},{"key":"e_1_3_1_210_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2021.10.020"},{"key":"e_1_3_1_211_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2020.241"},{"key":"e_1_3_1_212_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2021.10.014"},{"key":"e_1_3_1_213_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv267"},{"key":"e_1_3_1_214_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx409"},{"key":"e_1_3_1_215_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2023.154315"},{"key":"e_1_3_1_216_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11061459"},{"key":"e_1_3_1_217_2","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10071-24767"},{"key":"e_1_3_1_218_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw861"},{"key":"e_1_3_1_219_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70055-6"},{"key":"e_1_3_1_220_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm325"},{"key":"e_1_3_1_221_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/8.supplement_5.s612"},{"key":"e_1_3_1_222_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13050453"},{"key":"e_1_3_1_223_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2021.024"},{"key":"e_1_3_1_224_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.08.024"},{"key":"e_1_3_1_225_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn018"},{"key":"e_1_3_1_226_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2009.06.032"},{"key":"e_1_3_1_227_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197406202902502"},{"key":"e_1_3_1_228_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/143.2.141"},{"key":"e_1_3_1_229_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1979.50.1.0095"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01063-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01063-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:39:28Z","timestamp":1773178768000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01063-24"}},"subtitle":[],"editor":[{"given":"Pranita D.","family":"Tamma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":228,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,6]]}},"alternative-id":["10.1128\/aac.01063-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.01063-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"2025-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01063-24"}}